These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9583849)

  • 21. Nutritional management and pancreatic enzyme therapy in cystic fibrosis patients: state of the art in 1987 and projections into the future.
    George DE; Mangos JA
    J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S49-57. PubMed ID: 3042940
    [No Abstract]   [Full Text] [Related]  

  • 22. Essential fatty acid deficiency in well nourished young cystic fibrosis patients.
    Roulet M; Frascarolo P; Rappaz I; Pilet M
    Eur J Pediatr; 1997 Dec; 156(12):952-6. PubMed ID: 9453380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DeltaF508 CFTR Hetero- and Homozygous Paediatric Patients with Cystic Fibrosis Do Not Differ with Regard to Nutritional Status.
    Mędza A; Kaźmierska K; Wielgomas B; Konieczna L; Olędzka I; Szlagatys-Sidorkiewicz A; Sznurkowska K
    Nutrients; 2021 Apr; 13(5):. PubMed ID: 33919435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis.
    De Vizia B; Raia V; Spano C; Pavlidis C; Coruzzo A; Alessio M
    JPEN J Parenter Enteral Nutr; 2003; 27(1):52-7. PubMed ID: 12549599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes.
    Roy CC; Weber AM; Morin CL; Combes JC; Nusslé D; Mégevand A; Lasalle R
    N Engl J Med; 1977 Dec; 297(24):1301-5. PubMed ID: 917086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fatty acids composition of serum lipid fractions in children with cystic fibrosis of the pancreas before and after treatment with pancreatin].
    Annibaldi L; Antonelli M; Ballati G; Giardini O; Cardi E
    Riv Clin Pediatr; 1968; 81(5):962-4. PubMed ID: 5740224
    [No Abstract]   [Full Text] [Related]  

  • 27. Plasma fatty acids and lipid hydroperoxides increase after antibiotic therapy in cystic fibrosis.
    Durieu I; Abbas-Chorfa F; Drai J; Iwaz J; Steghens JP; Puget M; Ecochard R; Bellon G
    Eur Respir J; 2007 May; 29(5):958-64. PubMed ID: 17301094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatty acid composition of erythrocyte phospholipids from patients with cystic fibrosis.
    Hubbard VS; Dunn GD
    Clin Chim Acta; 1980 Mar; 102(1):115-8. PubMed ID: 7389104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation.
    Lancellotti L; D'Orazio C; Mastella G; Mazzi G; Lippi U
    Eur J Pediatr; 1996 Apr; 155(4):281-5. PubMed ID: 8777920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations.
    Winklhofer-Roob BM; van't Hof MA; Shmerling DH
    Am J Clin Nutr; 1996 May; 63(5):722-8. PubMed ID: 8615355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal lipid concentrations in cystic fibrosis.
    Figueroa V; Milla C; Parks EJ; Schwarzenberg SJ; Moran A
    Am J Clin Nutr; 2002 Jun; 75(6):1005-11. PubMed ID: 12036806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Faecal elastase-1 and fat-soluble vitamin profiles in patients with cystic fibrosis in Western Norway.
    Dorlöchter L; Aksnes L; Fluge G
    Eur J Nutr; 2002 Aug; 41(4):148-52. PubMed ID: 12242582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy.
    Aldámiz-Echevarría L; Prieto JA; Andrade F; Elorz J; Sojo A; Lage S; Sanjurjo P; Vázquez C; Rodríguez-Soriano J
    Pediatr Res; 2009 Nov; 66(5):585-9. PubMed ID: 19851226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis.
    Stapleton FB; Kennedy J; Nousia-Arvanitakis S; Linshaw MA
    N Engl J Med; 1976 Jul; 295(5):246-8. PubMed ID: 934188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparative study of the effect of kreon and cotazyme forte in children with cystic fibrosis].
    Zsíros J; Sólyom E
    Orv Hetil; 1988 May; 129(19):995-9. PubMed ID: 3290773
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis.
    Lepage G; Yesair DW; Ronco N; Champagne J; Bureau N; Chemtob S; Bérubé D; Roy CC
    J Pediatr; 2002 Aug; 141(2):178-85. PubMed ID: 12183711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of supplementing medium chain triglycerides with linoleic acid-rich monoglycerides on severely disturbed serum lipid fatty acid patterns in patients with cystic fibrosis.
    Christophe A; Verdonk G; Robberecht E; Mahathanakhun R
    Ann Nutr Metab; 1985; 29(4):239-45. PubMed ID: 4026204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of cimetidine as an adjunct to supplemental pancreatic enzymes in patients with cystic fibrosis.
    Hubbard VS; Dunn GD; Lester LA
    Am J Clin Nutr; 1980 Nov; 33(11):2281-6. PubMed ID: 7435406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements. A study of 16 patients in Israel.
    Sack J; Blau H; Goldfarb D; Ben-Zaray S; Katznelson D
    Isr J Med Sci; 1980 Jun; 16(6):417-9. PubMed ID: 6901713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current concepts: pancreatic extracts.
    Littman A; Hanscom DH
    N Engl J Med; 1969 Jul; 281(4):201-4. PubMed ID: 4892805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.